Full Issue PDF DOI Open Access

Advances in Pulmonary Hypertension, Год журнала: 2023, Номер 22(3), С. 1 - 32

Опубликована: Ноя. 1, 2023

Pulmonary hypertension (PH) is characterized by increased right ventricular (RV ) afterload, which accommodated early dramatic increases in RV contractility to maintain ventriculoarterial coupling.Related its tissue biology, characteristics of differ from those the left ventricle (LV ).As undergoes adaptation PH, echocardiographic signs emerge can help identify PH and be reassessed noninvasively prognosticate outcomes PH.Many these indices calculated standard views without significant modification scanning procedures.This review will discuss contemporary diagnosis highlighting role echocardiography this process.We describe differences between LV RV, including adaptations how factors impact assessment.We conclude with a discussion specific parameters their reassessment.Routine assessment heart improves noninvasive risk stratification may reduce delays diagnosis, ultimately potentially modifiable disease burden patient population.

Язык: Английский

Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment DOI Creative Commons
M Peracaula,

Laura Sebastián,

Iria Francisco

и другие.

Biomedicines, Год журнала: 2024, Номер 12(9), С. 1936 - 1936

Опубликована: Авг. 23, 2024

Pulmonary Embolism (PE) is a life-threatening condition initiated by the presence of blood clots in pulmonary arteries, leading to severe morbidity and mortality. Underlying mechanisms involve endothelial dysfunction, including impaired flow regulation, pro-thrombotic state, inflammation, heightened oxidative stress, altered vascular remodeling. These contribute diseases stemming from PE, such as recurrent thromboembolism, chronic thromboembolic hypertension, post-thrombotic syndrome, right heart failure, cardiogenic shock. Detailing key risk factors utilizing hemodynamic stability-based categorization, review aims for precise stratification applying established diagnostic tools scoring systems. This article explores both conventional emerging biomarkers potential tools. Additionally, synthesizing existing knowledge, it provides comprehensive outlook current enhanced PE management preventive strategies. The conclusion underscores need future research improve accuracy therapeutic effectiveness PE.

Язык: Английский

Процитировано

3

Prognosis of pulmonary hypertension in patients with hypertrophic cardiomyopathy: A multicenter propensity score matching study DOI Creative Commons
Huihui Ma,

Fengcheng Xu,

Lei Liu

и другие.

IJC Heart & Vasculature, Год журнала: 2025, Номер 56, С. 101605 - 101605

Опубликована: Янв. 15, 2025

Язык: Английский

Процитировано

0

Pulmonary hypertension and associated heart failure: New insights on emerging signalling pathways DOI Open Access
Rosalinda Madonna,

Elisa Montemaggi

European Journal of Clinical Investigation, Год журнала: 2025, Номер unknown

Опубликована: Март 28, 2025

Abstract Pulmonary hypertension associated with left heart disease (PH‐LHD) represents the hemodynamic condition at rest resulting from pathologies that affect ventricle and/or atrium. Among diseases, failure is most frequent cause of PH. PH‐LHD common PH, accounting for 65–80% diagnoses. Several drugs targeting specific signalling pathways involved in pulmonary remodelling PH‐LHD, including nitric oxide, MAP kinase and endothelin‐1, have been tested randomized clinical trials (RCTs), disappointing results terms efficacy safety. Therefore, still remains orphan therapies able to counteract pre‐ post‐capillary circulation. In this article, we will discuss pathophysiology molecular mechanisms PH‐LHD. We focus on emerging could suggest novel targets treatment condition.

Язык: Английский

Процитировано

0

Cardiopulmonary complications in cancer: from tumour pathogenesis to treatment-induced toxicity and clinical management DOI

Zhigang Mao,

Xuting Wang, Si Chen

и другие.

Postgraduate Medical Journal, Год журнала: 2025, Номер unknown

Опубликована: Май 31, 2025

Abstract This paper provides a comprehensive overview of cardiopulmonary events associated with the occurrence, development, and treatment tumours, serving as valuable resource for clinical management cancer patients. It explores complex relationship between heart lungs, collectively discussing implications linked to tumours. Common risk factors that connect tumours cardiac pulmonary conditions are delineated, highlighting their direct indirect correlations. Additionally, addresses disorders symptoms resulting from tumour progression subsequent manifestations. The final section focuses on repercussions various treatments, including chemotherapy, targeted therapy, radiation immunotherapy, elaborating effects. Effective aggressive proliferative diseases, such requires selecting appropriate modalities balance therapeutic efficacy vigilant monitoring function thorough assessment outcomes related side

Язык: Английский

Процитировано

0

Mirabegron for Cardiac Disease: A New Therapeutic Frontier DOI

Hadrian Hoang-Vu Tran,

Aung Myat Thu,

Axel Fuertes

и другие.

Cardiology in Review, Год журнала: 2025, Номер unknown

Опубликована: Июнь 4, 2025

Mirabegron, a selective β3-adrenergic receptor agonist approved for overactive bladder, is being investigated its cardiovascular applications, particularly in heart failure (HF) and left ventricular hypertrophy. This review explores the mechanistic rationale, safety profile, emerging clinical data supporting stimulation as novel therapeutic strategy. Unlike β1-blockers, mirabegron activates nitric oxide-dependent pathways that confer vasodilatory, antifibrotic, autonomic regulatory benefits, relevant HF with preserved ejection fraction. However, use raises concerns, including modest increases blood pressure, rate, QTc interval, especially high-risk cardiac populations. Early trials have shown improvements hemodynamic parameters such index pulmonary vascular resistance, neutral or favorable impact on symptoms function. Nevertheless, long-term safety, optimal patient selection, potential combination therapy established treatments remain unresolved. Future research must prioritize identifying biomarkers predictive of response, evaluating synergy current therapies, determining durability benefits. Mirabegron represents promising, mechanistically distinct approach to neurohormonal modulation HF, address gaps unmet by conventional therapies.

Язык: Английский

Процитировано

0

Pulmonary Hypertension in Left Heart Diseases: Pathophysiology, Hemodynamic Assessment and Therapeutic Management DOI Open Access
Zied Ltaief, Patrick Yerly, Lucas Liaudet

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(12), С. 9971 - 9971

Опубликована: Июнь 9, 2023

Pulmonary hypertension (PH) associated with left heart diseases (PH-LHD), also termed group 2 PH, represents the most common form of PH. It develops through passive backward transmission elevated pressures in setting failure, either preserved (HFpEF) or reduced (HFrEF) ejection fraction, which increases pulsatile afterload right ventricle (RV) by reducing pulmonary artery (PA) compliance. In a subset patients, progressive remodeling circulation resulted pre-capillary phenotype vascular resistance (PVR) further increasing RV afterload, eventually leading to RV-PA uncoupling and failure. The primary therapeutic objective PH-LHD is reduce left-sided appropriate use diuretics guideline-directed medical therapies for When established, targeted aiming PVR are theoretically appealing. So far, such have mostly failed show significant positive effects patients PH-LHD, contrast their proven efficacy other forms Whether may benefit some specific subgroups (HFrEF, HFpEF) hemodynamic phenotypes (post- PH) various degrees dysfunction still needs be addressed.

Язык: Английский

Процитировано

8

Plasma tumour necrosis factor‐alpha‐related proteins in prognosis of heart failure with pulmonary hypertension DOI Creative Commons
Adam Engel Sällberg,

Sara Helleberg,

Salaheldin Ahmed

и другие.

ESC Heart Failure, Год журнала: 2023, Номер 10(6), С. 3582 - 3591

Опубликована: Сен. 29, 2023

Patients with heart failure (HF) exhibit poor prognosis, which is further deteriorated by pulmonary hypertension (PH), negative impact on morbidity and mortality. As PH due to left HF (LHF-PH) among the most common causes of PH, there an urge according 2021 European Society Cardiology guidelines find new biomarkers that aid in prognostication this patient cohort. Given role tumour necrosis factor-alpha (TNF-α) progression, we aimed investigate prognostic value plasma proteins related TNF-α patients LHF-PH, relation haemodynamic changes following transplantation (HT).

Язык: Английский

Процитировано

3

Pediatric Pulmonary Hypertension in Left-Sided Heart Disease DOI Open Access

William F. Patten,

Usha Krishnan

Advances in Pulmonary Hypertension, Год журнала: 2023, Номер 22(3), С. 134 - 139

Опубликована: Ноя. 1, 2023

Pulmonary hypertension (PH) from left-sided heart disease (group-II PH) is an increasingly recognized cause of PH in pediatrics. Group-II can result obstruction at any level the left heart, and progress over time. Management be particularly difficult, as targeted therapy setting a fixed carries risk pulmonary vascular congestion edema. Based on existing evidence, use vasodilators group II not recommended, management centers around early identification correction underlying lesion. In this review, we highlight pathophysiology group-II PH, diagnostic evaluation pathology, general approach to both medical surgical management, with particular attention relevant lesions. multifaceted progressive process that poses difficult challenge clinicians, requires thoughtful individualized management.

Язык: Английский

Процитировано

1

Interventional therapies for chronic heart failure: An overview of recent developments DOI Creative Commons
Bingchen Guo, Si Shi, Yutong Guo

и другие.

ESC Heart Failure, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 11, 2024

Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results improving prognosis HF. These include transcatheter aortic valve replacement for severe stenosis, mitral repair chronic regurgitation, neuromodulation multiple targets measures treatment HF left ventricular assist device implantation advanced ( Figure 1 ). In this review, we aimed to provide an overview current progress therapies

Язык: Английский

Процитировано

0

Microvesicles and inflammatory markers in an animal model of chronic postcapillary pulmonary hypertension DOI Creative Commons

Elva María Mendoza Zambrano,

Belén Gómez Rodríguez,

I. Garcia Lunar

и другие.

International Journal of Medical Sciences, Год журнала: 2023, Номер 20(10), С. 1336 - 1338

Опубликована: Янв. 1, 2023

Язык: Английский

Процитировано

0